Madrigal Pharmaceuticals Announces New Analyses From Phase 3 MAESTRO-NASH Trial Of Resmetirom To Be Presented At EASL Congress, June 5-8, 2024 In Milan, Italy
$MDGL
Biotechnology: Pharmaceutical Preparations
Health Care
- Late-breaking AI-based analysis of MAESTRO-NASH biopsy data demonstrates Rezdiffra improved key fibrotic features that are predictive of progression to decompensated cirrhosis
- Noninvasive test data through three years of treatment demonstrate durable treatment response to Rezdiffra; 91% of patients achieved improvement or stabilization of liver stiffness
- First analysis of health-related quality of life data from MAESTRO-NASH demonstrates Rezdiffra improved patient worry, health distress and stigma
- First analysis of Rezdiffra treatment in MetALD demonstrates patients achieved similar rates of fibrosis improvement and steatohepatitis resolution compared to the NASH population